Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men
Alvin M Matsumoto,
Leon Flicker,
Kevin Murray,
Robert J Adams,
Magnus Karlsson,
Bu Beng Yeap,
Ross James Marriott,
Leen Antonio,
Christie M Ballantyne,
Shalender Bhasin,
Peggy M Cawthon,
David John Couper,
Adrian S Dobs,
Sean A Martin,
Dan Mellström,
Paul E Norman,
Claes Ohlsson,
Eric S Orwoll,
Terence W O'Neill,
Molly M Shores,
Thomas G Travison,
Dirk Vanderschueren,
Gary A Wittert,
Frederick C W Wu
Affiliations
Alvin M Matsumoto
Leon Flicker
WA Centre for Health & Ageing, Medical School, University of Western Australia, Perth, Western Australia, Australia
Kevin Murray
Robert J Adams
Magnus Karlsson
Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden
Bu Beng Yeap
Medical School, University of Western Australia, Perth, Western Australia, Australia
Ross James Marriott
School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia
Leen Antonio
Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium
Christie M Ballantyne
Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
Shalender Bhasin
Harvard Medical School, Boston, Massachusetts, USA
Peggy M Cawthon
San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California, USA
David John Couper
Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Adrian S Dobs
School of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA
Sean A Martin
Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia, Australia
Dan Mellström
Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Goteborg, Sweden
Paul E Norman
Medical School, University of Western Australia, Perth, Western Australia, Australia
Claes Ohlsson
Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Goteborg, Sweden
Eric S Orwoll
Oregon Health & Science University, Portland, Oregon, USA
Terence W O'Neill
Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester, UK
Molly M Shores
VA Puget Sound Health Care System, Seattle, Washington, USA
Thomas G Travison
Harvard Medical School, Boston, Massachusetts, USA
Dirk Vanderschueren
Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Flanders, Belgium
Gary A Wittert
Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia, Australia
Frederick C W Wu
Division of Diabetes, Endocrinology and Gastroenterology, The University of Manchester, Manchester, UK
Introduction This study aims to clarify the role(s) of endogenous sex hormones to influence health outcomes in men, specifically to define the associations of plasma testosterone with incidence of cardiovascular events, cancer, dementia and mortality risk, and to identify factors predicting testosterone concentrations. Data will be accrued from at least three Australian, two European and four North American population-based cohorts involving approximately 20 000 men.Methods and analysis Eligible studies include prospective cohort studies with baseline testosterone concentrations measured using mass spectrometry and 5 years of follow-up data on incident cardiovascular events, mortality, cancer diagnoses or deaths, new-onset dementia or decline in cognitive function recorded. Data for men, who were not taking androgens or drugs suppressing testosterone production, metabolism or action; and had no prior orchidectomy, are eligible. Systematic literature searches were conducted from 14 June 2019 to 31 December 2019, with no date range set for searches. Aggregate level data will be sought where individual participant data (IPD) are not available. One-stage IPD random-effects meta-analyses will be performed, using linear mixed models, generalised linear mixed models and either stratified or frailty-augmented Cox regression models. Heterogeneity in estimates from different studies will be quantified and bias investigated using funnel plots. Effect size estimates will be presented in forest plots and non-negligible heterogeneity and bias investigated using subgroup or meta-regression analyses.Ethics and dissemination Ethics approvals obtained for each of the participating cohorts state that participants have consented to have their data collected and used for research purposes. The Androgens In Men Study has been assessed as exempt from ethics review by the Human Ethics office at the University of Western Australia (file reference number RA/4/20/5014). Each of the component studies had obtained ethics approvals; please refer to respective component studies for details. Research findings will be disseminated to the scientific and broader community via the publication of four research articles, with each involving a separate set of IPD meta-analyses (articles will investigate different, distinct outcomes), at scientific conferences and meetings of relevant professional societies. Collaborating cohort studies will disseminate findings to study participants and local communities.PROSPERO registration number CRD42019139668.